Previous 10 | Next 10 |
The stock performance of BioMarin (NASDAQ: BMRN) was less than healthy on Thursday. Shares of the biotech, which specializes in treatments for rare diseases, fell by more than 6% after management delivered an earnings release that did not please investors. After the close of tra...
BioMarin Pharmaceutical Inc. (BMRN) Q4 2021 Results Conference Call February 23, 2022 04:30 PM ET Company Participants Traci McCarty - Vice President of Investor Relations J.J. Bienaime - Chairman and Chief Executive Officer Jeff Ajer - Executive Vice President and Chief Commercial Officer Ha...
BioMarin Pharmaceutical press release (NASDAQ:BMRN): Q4 GAAP EPS of -$0.32 beats by $0.02. Revenue of $449.8M (-0.5% Y/Y) beats by $7.42M. For FY2022, the company expects revenue between $2.05B to $2.15B vs. consensus of $2.13B and Non-GAAP income to be between $350M to $390M. For further d...
BioMarin Announces Fourth Quarter and Full Year 2021 Financial Results and Corporate Updates - Full-year 2021 Total Revenues of $1.85 Billion; Revenues Excluding Kuvan Increased 11% Year-Over-Year - Company Provides Full-Year 2022 Total Revenue Guidance of $2.05 Billion to $...
The FDA is requesting BioMarin Pharmaceutical (NASDAQ:BMRN) provide additional data to lift a clinical hold on a phase 1/2 study of candidate BMN 307 issued in September 2021. "The FDA has requested data from additional non-clinical studies to assess the theoretical oncogenic risk to human st...
BioMarin Provides Updates on Progress in Gene Therapy Programs PR Newswire SAN RAFAEL, Calif. , Feb. 17, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced updates on its investigational gene therapy programs in clinical development. ...
Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) traded today at $92.73, eclipsing its 52-week high. This new high was reached on below average trading volume as 228,000 shares traded hands, while the average 30-day volume is approximately 1.3 million shares. BioMarin Pharmaceutical ...
BioMarin to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on Wednesday, February 23 at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , Feb. 10, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced...
BioMarin Sells Priority Review Voucher for $110 Million PR Newswire SAN RAFAEL, Calif. , Feb. 9, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that it has entered into a definitive agreement with an undisclosed purchaser to ...
Investing in the biotech industry is an art, not a science. While the potential for gains from groundbreaking therapies exists, the majority fail. By utilizing statistics, careful selection, and net present value calculations, it is quite easy to find a basket that fulfills your p...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
BioMarin Pharmaceutical Inc. Website:
BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , July 23, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander ...
2024-07-10 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-27 14:15:03 ET Scotiabank analyst issues UNDERPERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Underperform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus : BU...